Table 2.

CfB in selected EEG parameters for the Fz electrode at EoT.

	MMN amplitude			ASSRa (40 Hz stimulation)			Resting state power in gamma band
	Duration (µV)	Frequency (µV)	Duration + frequency (µV)	Induced power (dB)	Evoked power (dB)	Phase-locking factor	Absolute power (µV2)	Relative power (%)
Total patients (N = 79)
Nb	47	46	47	37			57
Mean	−0.02	0.17	−0.10	0.15	−0.09	−0.00	−0.02	−0.23
SEM	0.21	0.20	0.25	0.20	1.20	0.01	0.26	0.25
SD	1.41	1.33	1.70	1.20	7.27	0.07	1.93	1.88
Min	−2.54	-3.21	−4.89	−1.87	−12.21	−0.13	−6.21	−11.52
Max	3.31	3.23	3.28	4.03	13.02	0.19	10.29	4.81
Placebo (N = 20)
Nb	12			10			15
Mean	−0.22	0.68	0.29	0.26	0.79	0.01	−0.76	−0.46
SEM	0.40	0.47	0.61	0.45	2.25	0.03	0.28	0.25
SD	1.38	1.62	2.11	1.42	7.13	0.08	1.10	0.96
Min	−2.18	−2.17	-3.82	−1.87	−10.91	−0.07	−3.97	−3.20
Max	1.70	2.94	3.28	3.41	11.83	0.19	0.83	1.23
Iclepertin 10 + 25 mg (N = 35)
Nb	21			15			26
Mean	−0.01	0.33	-0.08	0.01	−2.09	−0.01	0.24	−0.43
SEM	0.30	0.23	0.40	0.20	1.78	0.02	0.50	0.47
SD	1.36	1.05	1.84	0.76	6.90	0.06	2.56	2.41
Min	−2.54	−1.59	−4.89	−1.53	−12.21	−0.13	−6.21	−11.52
Max	1.72	3.23	2.79	0.99	12.33	0.09	10.29	2.15

ASSR auditory steady-state response, CfBchange from baseline; EEG electroencephalography; EoT end of treatment, MMN mismatch negativity, SD standard deviation; SEM standard error of the meanASSR, auditory steady-state response; CfB change from baseline, EEG electroencephalography, EoT end of treatment, MMN mismatch negativity, SD standard deviation, SEM standard error of the mean.

^aBaseline-corrected.

^bNumber of patients with analyzable data for each EEG parameter.